| Document |
Document Title |
|
WO/2010/021093A1 |
Provided are a novel asymmetric organic catalyst with which it is possible to realize a high optically-active yield when said catalyst is used in a small amount, and a method for producing a compound using the same. The asymmetric organi...
|
|
WO/2010/020370A1 |
The invention relates to a method for storing and/or transporting intramolecular cyclic esters (lactones), in particular lactides.
|
|
WO/2010/020548A1 |
The present invention relates to a compound of the general formula (I) wherein R1/R2 are independently from each other lower alkyl, or form together with the N-atom to which they are attached a heterocyclic group, selected from pyrrolidi...
|
|
WO/2010/019911A2 |
The present invention includes compositions and methods for inhibiting kinase activity to protect against neurodegeneration including diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease, and conditions such...
|
|
WO/2010/018209A1 |
The present invention relates to a method of obtaining lactide using a solvent from the family of ethers, starting from a mixture that is in the liquid form comprising lactide, meso-lactide and other impurities.
|
|
WO/2010/011548A1 |
The present invention is directed to novel substituted sulfamide derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives form in the treatment of anxiety and related disorders; bipolar depress...
|
|
WO/2010/003299A1 |
An organic compound and preparation method thereof, particularly a flavor enhancer and preparation method thereof, are disclosed. Its chemical name is 4-isopropyl-5,5-dimethyl-m-dioxan-2-one. It is prepared by the following method: start...
|
|
WO/2010/003624A2 |
Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, ...
|
|
WO/2010/000193A1 |
The invention provides a process for preparing osemozotan and its pharmaceutically acceptable salts. The invention also provides an intermediate, (2R)-N-[3-(1,3- benzodioxol-5-yloxy)propyl]-1,4-benzodioxin-2-formamide, used in the proces...
|
|
WO/2009/153886A1 |
A process for producing an α-hydroxy acid that is economically advantageous without the secondary production of a large volume of waste, having satisfactory quality as a polymer raw material. The process for producing an α-hydroxy acid...
|
|
WO/2009/150248A1 |
The present invention relates to a compound of general formula (I) : and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in particular to an enantiomer mixture, and esp...
|
|
WO/2009/150966A1 |
Disclosed is a liquid crystalline compound which is stable against heat, light or the like and has a nematic phase in a wide temperature range, while having a low viscosity, a large optical anisotropy, an adequate elastic constant K33, a...
|
|
WO/2009/150963A1 |
Disclosed is a liquid crystal compound having general physical properties necessary for a compound, stability against heat, light or the like, a wide temperature range of a liquid crystal phase, a high clearing point, good compatibility ...
|
|
WO/2009/133109A1 |
The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention re...
|
|
WO/2009/133110A1 |
The present invention relates to novel1-(4H-1,3-benzodioxin-2-yl)methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically asdopaminergic stabilizers. In other aspects the invention relates to the...
|
|
WO/2009/133107A1 |
The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)- methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention r...
|
|
WO/2009/130422A2 |
The present invention relates to the use of acylthiourea or acylurea derivatives of formula (I) for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, an...
|
|
WO/2009/129726A1 |
The present invention provides novel nitrones, their preparation and use. The novel compounds have the following formula: I The compounds of the present invention have strong antioxidative activity, and are thrombolytic. These compounds ...
|
|
WO/2009/128521A1 |
Disclosed are: a compound having an excellent inhibitory activity on cysteine protease; and a pharmaceutical agent for the treatment or prevention of a disease selected from the group consisting of osteoporosis, osteoarthrosis deformans,...
|
|
WO/2009/120191A1 |
The present invention is directed to a process for the preparation of benzo-fused heteroaryl sulfamates, useful for the treatment of epilepsy and related disorders according to formula (IA) and to a crystalline compound of formula (I-S)....
|
|
WO/2009/120192A2 |
The present invention is directed to processes for the preparation of benzo-fused heteroaryl derivatives, useful for the treatment of epilepsy and related disorders. The present invention is further directed to processes for the preparat...
|
|
WO/2009/117829A1 |
Compounds having the general formula (I): wherein X is S, Se or NH, and stereoisomers thereof, and de-O-sulfonated analogues of all of the foregoing, but excluding naturally occurring kotalanol and de-O-sulfonated kotalanol, and methods ...
|
|
WO/2009/117902A1 |
Provided herein are 5-demethoxyfumagillol and its derivatives. Also provided herein are methods of making the 5-demethoxyfumagillol and derivatives. Also provided herein are biological activities of the 5-demethoxyfumagillol and derivati...
|
|
WO/2009/111830A1 |
The present invention relates to a class of conjugated unsaturated compounds, to a method of preparing such compounds, and to the polymerisation and bio-active uses of such compounds including their use as antimicrobial agents. The inven...
|
|
WO/2009/104722A1 |
Provided are 1) polymer compounds having excellent acid reactivity and thermal stability as well as minimal swelling during development, 2) compounds of the following formula that serve as starting materials for said polymer compounds, a...
|
|
WO/2009/089210A1 |
The present invention is directed to novel processes for the preparation of sulfamide derivatves, useful in the treatment of epilepsy and related disorders.
|
|
WO/2009/084773A2 |
The present invention relates to a preparation process useful in synthesis of atorvastatin, more particularly a process for preparing atorvastatin is effective in treating hyperlipemia, comprising protecting the dihydroxy group at C3 and...
|
|
WO/2009/080834A1 |
Process for the synthesis of a cyclic diester of an alpha-hydroxyacid, comprising the following steps: an alkalino-earth salt of the corresponding alpha-hydroxyacid is mixed with said alpha-hydroxyacid and water; the mixture is treated b...
|
|
WO/2009/077385A1 |
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...
|
|
WO/2009/077615A1 |
The present invention relates to a method for obtaining lactide by thermal cracking of lactic acid oligomers in the presence of a metal salt of the phosphite anion (PO3)3- in which the metal is chosen from the group comprising tin, alumi...
|
|
WO/2009/075818A1 |
Disclosed herein are methods and intermediates useful in the preparation of macrolides, e.g., compounds of formula (IV) wherein R1-R12 are as defined herein.
|
|
WO/2009/070910A2 |
Compounds of formula (I) wherein R1- R5, n and m have the same meaning as given in the description, having cooling properties are disclosed. Furthermore a process of their production and consumer products comprising them are disclosed.
|
|
WO/2009/072502A1 |
Disclosed is a method by which various fluorine-containing carbonate compounds can be freely produced with high yield without using phosgene and without by-producing hydrogen chloride. Specifically disclosed is a method wherein a fluorin...
|
|
WO/2009/072501A1 |
Disclosed is a novel method by which various carbonate compounds can be freely produced with high yield without using phosgene and without by-producing hydrogen chloride. Specifically disclosed is a method wherein a compound having a car...
|
|
WO/2009/062224A1 |
The invention relates to a method for producing L,L-, D,D-, D,L- or meso-dilactide, comprising polycondensation and/or polytransesterification of L-, D- or D,L-lactic acid or esters thereof to form high-molecular-weight polyesters of L-,...
|
|
WO/2009/065035A1 |
The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders, such as cancer.
|
|
WO/2009/064031A1 |
There is provided a compound having an excellent controlling effect on pests, represented by the formula (I): wherein, A and E independently represent a -R1 group, a -L1-R1 group, etc.; G represents a -L2-R1 group, a -S(O)2-R4 group, etc...
|
|
WO/2009/053250A1 |
The invention relates to compounds of the formula (I), in which the substituents have the meanings given in the description, method for producing said compounds, agents comprising the same, and the use thereof to combat damaging fungi.
|
|
WO/2009/035951A2 |
Disclosed are amide, thioamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and co...
|
|
WO/2009/031437A1 |
Disclosed is a liquid crystalline compound which has stability to heat, light and the like, exhibits a nematic phase in a wide temperature range, has a low viscosity, adequate optical anisotropy and an adequate elastic coefficient K33, a...
|
|
WO/2009/030396A1 |
The present invention relates to a method for the production or purification of biodegradable, intramolecular cyclic esters of alpha-hydroxycarboxylic acids, biodegradable alpha-hydroxycarboxylic acids or oligopolymers or polymers thereo...
|
|
WO/2009/030330A1 |
The invention relates to a condensation and washing device which can recycle and clean, in particular, process steam that is produced during the production of polylactide. The invention also relates to a polymerisation device for produci...
|
|
WO/2009/024492A1 |
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...
|
|
WO/2009/022311A2 |
The invention relates to 1,2-diamido-ethylene derivatives of the formula (I) wherein R1, R 2, R 3, and A are as described in the description and their use as medicaments, especially as orexin receptor antagonists.
|
|
WO/2009/019561A2 |
The present invention is directed to a 2-deoxyribose-5-phosphate aldolase (DERA) chemoenzymatic process for making chiral compounds.
|
|
WO/2009/017261A1 |
The present invention relates to a method for preparing ultrafine p-dioxanone. The method comprises the steps of performing dehydrogenation cyclization of diethylene glycol in the presence of a pure silica catalyst (SiO ) or a copper-chr...
|
|
WO/2008/145941A9 |
The invention relates to a conjugated process for the production of nitriles and/or of fatty amines and of polyol carbonates from a natural oil, comprising the following zones: I) zone of methanolysis or hydrolysis of a natural oil conta...
|
|
WO/2009/010527A1 |
The present invention relates to a process for preparing cyclic glycerol acetals or cyclic glycerol ketals or mixtures thereof and cyclic glycerol monoester acetals or monoether acetals or cyclic glycerol monoester ketals or monoether ke...
|
|
WO/2009/004990A1 |
It is intended to provide a prostaglandin F2α receptor agonist (FP receptor agonist), which comprises a biphenyl derivative represented by the following general formula (I) (wherein m represents an integer of 0 to 2; n represents an int...
|
|
WO/2008/155818A1 |
A preventive or therapeutic agent for frequent urination and urinary incontinence containing as an active ingredient, a 1,4-benzodioxine derivative represented by the general formula (I): (wherein A represents an aryl group or a C3-8 cyc...
|
